DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distributio

DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.
Market Dynamics
Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.
Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.
Key features of the study:
This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global DNA repair drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation:
Global DNA Repair Drugs Market, By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
Global DNA Repair Drugs Market, By Application:
Ovarian Cancer
Breast Cancer
Global DNA Repair Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global DNA Repair Drugs Market, By Region:
North America
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America

Europe
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
By Application:
Ovarian Cancer
Breast Cancer
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
AstraZeneca Plc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Johnson & Johnson
GlaxoSmithKline plc.
Pfizer, Inc.
Clovis Oncology Inc.
AbbVie Inc.
Bristol Myers Squibb
Merck KGaA
Genentech, Inc.
Artios Pharma
Repare Therapeutics Inc.
Sierra Oncology, Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.